Exclusive Summary

• Best-in-class Photoimmunotherapy (PIT) Platform: UB648 features a novel fluorescent photosensitizer and a site-specific cleavable linker, offering dual-layer specificity (antibody + targeted NIR light) to completely bypass traditional systemic toxicities.
• Pipeline-in-a-product versatility: Targeting a pan-specific T-cell antigen allows it to address multiple indications. Lead indications are Cutaneous T-cell Lymphoma (CTCL) and Alopecia Areata (AA), with the potential to establish a highly lucrative front-line paradigm.
• Unique Theranostic & Safety Profile: Highly differentiated from main competitors (e.g., Rakuten's IR700), delivering superior cellular specificity without the debilitating local edema, while doubling as an imaging agent for real-time tracking.
• Compelling Proof of Concept & IP: Although Pre-IND, ex vivo human biopsies (90% targeted T-cell depletion) and in vivo models show remarkable efficacy and tissue-sparing. Backed by owned IP with Freedom to Operate (FTO) and easy manufacturability.
• Significant Out-licensing & Synergy Potential: The modality is bio-orthogonal, making it an extremely attractive asset for global pharma companies looking to license novel standalone therapies for autoimmune/dermatology markets, or as a combination to prime immuno-oncology drugs.

Asset Materials

Contact Us for Full Materials